8-K: Inari Medical Announces CFO Retirement and Succession Plan

Inari Medical's Chief Financial Officer, Mitch Hill, will retire on October 1, 2024, and will be succeeded by Kevin Strange, the current SVP of Finance, Accounting, Strategy and Business Development.

Summary

• Inari Medical has announced that its Chief Financial Officer, Mitch Hill, will retire effective October 1, 2024.
• Kevin Strange, currently the Senior Vice President of Finance, Accounting, Strategy and Business Development, will succeed Mr. Hill as CFO on the same date.
• Mr. Hill will remain in a non-executive role until January 2, 2025, to assist with the transition.
• Mr. Strange's new employment agreement includes an annual base salary of $480,000, a target bonus of 60% of his base salary, a one-time RSU grant valued at $250,000, and a one-time cash bonus of $300,000 for relocation expenses.
• Mr. Strange has been with Inari since 2020 and has held various leadership roles within the company.
• The company also announced its second quarter 2024 financial results in a separate press release.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the planned and orderly transition of the CFO role, the appointment of a qualified internal candidate, and the company's confidence in future growth.

Positives

• The transition plan includes a period where the outgoing CFO will support the new CFO, ensuring a smooth handover.
• Kevin Strange has a strong background in finance and business development within the medical device industry.
• Mr. Strange has been with Inari since 2020 and has a deep understanding of the company's operations.
• The company is providing a competitive compensation package to attract and retain top talent.

Negatives

• The departure of a long-serving CFO could create some uncertainty during the transition period.

Risks

• There is a risk of disruption during the CFO transition, although the company is taking steps to mitigate this.
• The company will need to ensure that the new CFO can maintain the same level of financial oversight and strategic guidance as the previous CFO.

Future Outlook

The company expects a seamless transition of the CFO role and anticipates continued growth under the new leadership.

Management Comments

• Drew Hykes, Inari CEO, stated that Mitch Hill helped build and scale a robust financial, operating, and technology foundation for Inari.
• Drew Hykes expressed confidence in Kevin Strange's leadership as the next CFO.
• Kevin Strange stated he is excited and honored to be named as Inari's next CFO and is committed to the company's mission.

Industry Context

The medical device industry often sees leadership changes as companies grow and evolve, and this transition at Inari is part of that natural progression. The appointment of an internal candidate suggests a focus on continuity and stability.

Comparison to Industry Standards

• The compensation package for Kevin Strange is competitive with other CFO roles in the medical device industry.
• The transition plan, with the outgoing CFO supporting the new CFO, is a common practice to ensure a smooth handover.
• Companies like Boston Scientific and Medtronic, where Kevin Strange previously worked, are benchmarks in the medical device sector, suggesting he brings valuable experience.

Management Changes

Stakeholder Impact

• Shareholders may view the planned transition positively due to the continuity and experience of the new CFO.
• Employees may experience a smooth transition with the outgoing CFO supporting the new CFO.
• Customers and suppliers are unlikely to be directly impacted by this change.

Next Steps

• Kevin Strange will assume the role of CFO on October 1, 2024.
• Mitch Hill will continue in a non-executive role until January 2, 2025.
• The company will file the employment agreement with Kevin Strange as an exhibit to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

Key Dates

Keywords

CFO, Chief Financial Officer, executive transition, finance, medical device, leadership, succession, Inari Medical, NARI